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Abstract The treatment of immunotherapy relapsed cutaneous melanoma constitutes a
challenge in both research and clinical practice fields given the lack of effective therapeutic
options. Homologous recombination deficiency (HRD) has been identified in several solid
cancers including cutaneous melanoma. However, the utility of medications targeting
HRD cancer cells is an uncharted territory inmelanoma.Moreover, preclinical evidence sug-
gests a synergistic role of combining immune checkpoint blockade (ICB) with drugs target-
ing HRD cancer cells such as PARP inhibitors. Here, we present a case study of a patient with
immunotherapy relapsedmelanoma whowas found to have detected HRD and was treated
with nivolumab (ICB) and olaparib (PARP inhibitors).
INTRODUCTION
Immune checkpoint blockade (ICB) has revolutionized the management of malignant cu-
taneous melanoma leading to significantly improved clinical outcomes. The long-term fol-
low-up studies in patients with metastatic melanoma treated with ICB have demonstrated
prolonged and durable responses. For example, the 5-yr survival data with combined nivo-
lumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) in the CheckMate-067 study has
shown a median overall survival (OS) of >60 mo in patients with metastatic melanoma
(Larkin et al. 2019). Similarly, the 5-yr follow-up in the KEYNOTE-001 trial of patients
with metastatic melanoma who were treated with pembrolizumab (PD-1 inhibitor) showed
a median OS of 38.6 mo in treatment-naive patients (Hamid et al. 2019). Despite these
remarkable results, a significant number of patients will eventually stop responding to
ICB and develop progressive disease. This has generated an unmet need for novel effec-
tive treatment options for patients who develop acquired resistance to immunotherapy.
Moreover, primary resistance to immunotherapy is another challenge that hinders the ef-
ficacy of ICB in melanoma patients.
Homologous recombination deficiency (HRD) refers to the intracellular state in which
cancer cells acquire defects in DNA-damage repair mechanisms. Mutations in the
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DNA-damage response (DDR) genes as well as other factors like epigenetic alterations could
lead to vulnerabilities in DNA repair mechanisms, which lead to HRD status in tumor cells
(Pilié et al. 2019). The poly(ADP-ribose) polymerase (PARP) inhibitors are a class of medica-
tion that target nuclear proteins involved in the repair of DNA single-stranded and double-
stranded breakage. These medications have demonstrated clinical efficacy in ovarian,
breast, and pancreatic cancers with defects in the homologous recombination pathway
due to BRCA1/2 mutations (Pilié et al. 2019).
In regards tomelanoma, Heeke et al. investigated HRD frequency by next-generation se-
quencing (NGS) in multiple tumors and found that mutations in the DDR genes are common-
ly prevalent in melanoma (18.1%, n=670) (Heeke et al. 2018). Similarly, analysis of The
Cancer Genome Atlas (TCGA) found a high number of mutations in different DDR pathways
in melanoma including mutations in the homologous-recombination, nucleotide-excision-
repair, and mismatch-repair genes (Knijnenburg et al. 2018). In addition, there is mounting
preclinical evidence of a synergistic role with combination ICB and PARP inhibitors to im-
prove antitumor immunity (Li et al. 2019).
This raises the question of whether combination ICB and PARP inhibitors have efficacy in
melanoma with HRD status after progression on immunotherapy.
We previously reported radiological response and mutation clearance after treatment
with nivolumab and olaparib in a patient with immunotherapy relapsed melanoma who
had a high HRD score due to a germline mutation in CHEK2 and several somatic mutations
in DDR genes (Khaddour et al. 2021). Here, we present our new observation in a 42-yr-old
male with metastatic melanoma who had evidence of borderline high HRD score and was
treated with nivolumab and olaparib after progression on prior ICB (nivolumab). Unlike the
previous report, our current patient had a high HRD score despite the absence of mutations
in DDR genes and had near-complete response. Liquid biopsy demonstrated mutations
cleared after treatment with nivolumab and olaparib.
RESULTS
Clinical Presentation
A 42-yr-old male was diagnosed with cutaneous melanoma in February 2017 (cT3aN2CM0:
Stage IIIC), which was treated with wide surgical excision followed by adjuvant therapy with
ipilimumab. He had grade IV colitis after the second cycle of ipilimumab, which required pro-
longed hospitalization and permanent discontinuation of cancer treatment. He continued
surveillance without any evidence of recurrence of melanoma until September 2020 when
computed tomography (CT) showed a 1.3-cm right paratracheal lymph node without pres-
ence of any other lesions (Fig. 1A). Biopsy was performed and pathology showed metastatic
melanoma. NGS revealed BRAF-wild type. The patient started nivolumab (480 mg IV, every
4 wk). Repeat imaging after two cycles showed increase in the size of the paratracheal node,
a new lung lesion, and multiple new hypodense hepatic lesions consistent with disease pro-
gression (Fig. 1A,C). HRD testing on the sequencing data from a Tempus xT test showed ge-
nome-wide loss of heterozygosity (LOH) at 32.9%. Based on this LOH score, the patient
started off-label combination nivolumab (480 mg IV, every 4 wk) and olaparib (300 mg
PO, twice daily). After 2 mo, CT demonstrated interval response and decrease in size of
the paratracheal node, resolution of a left lower lobe pulmonary nodule, and near-com-
plete/complete resolution of multiple hepatic hypoattenuating lesions (Fig. 1A,C).
Longitudinal circulating tumor DNA (ctDNA) assessment revealed clearance of all previously
detected mutations (Fig. 1B).
The patient developed grade III hepatitis before his third cycle of treatment, which
required discontinuation of cancer therapy and treatment with steroids with complete
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resolution of the immune therapy–related adverse event. Repeat CT after 2 mo of
treatment discontinuation demonstrated no lesions in the liver and stable disease in the
lungs.
Genomic Analysis
An NGS panel of 596 genes identified mutations in TERT (c.-124C>T, VAF 73.1%) ,
PIK3CA (p.H1047R, VAF 24.1%), NRAS (p.G12D, VAF 55.5%), TET2 (p.Q1445∗, VAF
37.5%), SETD2 (p.K916fs, VAF 17.8%), and CDKN2A copy-number loss, in addition to mi-
crosatellite stable (MSS) and tumor mutation burden (TMB) of 27.4 m/MB (Tempus xT).
Also, testing of HRD (Tempus xT) revealed genome-wide LOH of 32.9% nominally below
the 33% threshold required for the HRD status to be detected in cancer types other than
breast, ovarian, and pancreatic (defined by commercial vendor). Liquid biopsy analysis of
ctDNA in December 2020 demonstrated pathogenic mutations and variants of unknown
significance (VUSs) (Table 1). These mutations included NRAS (G12D) (VAF 0.6%), TERT
(promoter SNV) (VAF 0.6%), and detected additional somatic mutations in AR (E643K)
(VAF 0.9%), ROS1 (E2232K VAF 0.8% and G227S VAF 0.3%), and EGFR (Q208Q) (VAF
Figure 1. (A) Cross-sectional computed tomography of the chest: The upper image demonstrates right para-
tracheal lesionwithout compressive features prior to starting nivolumabmonotherapy, themiddle image dem-
onstrates an increase in the size of the paratracheal lesion after two cycles of nivolumab, and the lower image
demonstrates near-complete resolution of the right paratracheal lymph node after 2 mo of combined treat-
ment with nivolumab and olaparib (arrows). (B) Tumor response map using Guardant 360 showing several
somatic mutations detected on liquid biopsy (gray solid line) prior to starting treatment with nivolumab and
olaparib. All detected somatic mutations were cleared 2 mo after initiating nivolumab and olaparib (blue
line). (C ) Cross-sectional computed tomography of the abdomen demonstrating (upper images) new hepatic
lesions prior to starting nivolumab and olaparib, which were not present before starting nivolumabmonother-
apy. The lower images show near-complete and complete resolution of multiple hepatic lesions after 2 mo of
combined treatment with nivolumab and olaparib (arrows). (ND) Not detected, (SNV) single-nucleotide
variant.
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0.6%) as shown in Fig. 1B (Guardant360). The follow-up liquid biopsy using Guardant360
showed clearance of detected somatic mutations and VUSs after 1 and 2 mo of treatment
with nivolumab and olaparib. Of note, Guardant360 panel does not capture mutations in
TET2 and SETD2.
DISCUSSION: COMBINATION CHECKPOINT INHIBITORS AND PARP INHIBITORS
IN THE TREATMENT OF MELANOMAWITH DETECTED HRD
Response to olaparib (PARP inhibitor) in melanoma patients has been previously reported
when used as monotherapy and in combination with ICB (Khaddour et al. 2021; Lau et al.
2021). The previously reported patients had high LOH scores of 28.4% and 26.5%.
Interestingly in the current report, there were no detected mutations in DDR genes unlike
the previous reports that identified somatic mutations in DDR genes such as PALB2,
BRCA2, ATRX, and germline mutation in CHEK2. Notably, mechanisms other than DDR
gene mutations, such as epigenetic alterations like DNA hypermethylation, could contribute
to HRDness in cancer cells (Moschetta et al. 2016; Sahnane et al. 2020). Therefore, our ob-
servation is intriguing as it highlights the potential detection of HRD status without the pres-
ence of genetic alterations in DDR genes as well as the need for establishing an LOH
threshold specific to melanoma. Olaparib in combination with bevacizumab is currently ap-
proved for HRD-positive advanced ovarian cancer based on significant improvement in pro-
gression-free survival (PFS; 37.2 mo vs. 17.7 mowith bevacizumab alone) (Ray-Coquard et al.
2019).
PARP inhibitors can enhance sensitivity in the tumor microenvironment to ICB through a
variety of mechanisms including increased chromosomal aberrations due to deficiency in
DNA repair pathways, and modulation of immune response in the tumor microenvironment
(Teo et al. 2018; Chabanon et al. 2019). In addition, the presence of HRD in cancer cells as
well as the use of PARP inhibitor–induced synthetic lethality could lead to neoantigen forma-
tion that may resensitize tumor cells to ICB (Kakoti et al. 2020).
Finally, a recent study replicated previous findings of the common prevalence of HR-
DDR gene mutations in melanoma and fond a frequency of 21.4% (18 of 84 patient sam-
ples). This study also showed that PARP inhibitors could have efficacy in melanoma cell
lines harboring mutations in the HR-DDR genes, which suggests a possible role for
PARP inhibitors monotherapy in cutaneous melanoma (Kim et al. 2021). However, the
role of PARP inhibitors in metastatic melanoma with HRD status requires further validation
both in vitro and in vivo and in well-designed prospective clinical trials with larger cohorts.
Several questions remain to be answered as to whether the addition of ICB to PARP inhib-
itors has any added benefit to monotherapy with PARP inhibitors. Another challenge is the










NRAS Chr 1:115258747 c.35G>A G12D Pathogenic Substitution rs121913237 Heterozygous
TERT Chr 5:1295228 c.124C>T Promoter-124C>T Pathogenic Promoter/gene regulation rs1242535815 Heterozygous
ROS1 Chr 6:117622176 c.6694G>A E2232K VUS Substitution rs1275344272 Heterozygous
ROS1 Chr 6:117718178 c.679G>A G227S VUS Substitution Not available Heterozygous
AR Chr X:66931285 c.1927G>A E643K VUS Substitution rs2076093229 Heterozygous
(VUS) Variant of unknown significance.
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absence of a unified test of HRDness in tumor specimens and the lack of insight on a re-
liable cutoff point that could potentially help select patients who could benefit from
therapy targeting the homologous recombination repair (HRR) pathway. Finally, we ac-
knowledge the limitation in our observation given that it is a single case study, the absence
of a comparative arm, and the possibility that the observed response could have been a
delayed effect of ICB. In addition, it is important to mention the pseudoprogression phe-
nomenon that results from tumor infiltration with immune cells after treatment with ICB and
could be misinterpreted on imaging as true progression (Nishino et al. 2019). Our patient
developed multiple new scattered hepatic lesions after starting nivolumab, which makes
pseudoprogression unlikely but cannot be completely excluded per iRECIST criteria
(Seymour et al. 2017).
In conclusion, we describe a case of a patient with immunotherapy relapsed melanoma
with detected HRD in the absence of mutations in DDR genes who was treated with nivolu-
mab and olaparib. The patient had radiological response and mutation clearance by NGS
2 mo after initiation of therapy. Before the third cycle, the patient developed grade III hep-
atitis during treatment, which required discontinuation of therapy. This observation suggests
the need for further investigation to assess the safety and efficacy of ICB and PARP inhibitor
combination in immunotherapy relapsed melanoma with detected HRD. Currently, several
clinical trials are ongoing to evaluate the efficacy of PARP inhibitors and ICB in HRDmelano-
ma (NCT04633902 and NCT04187833).
METHODS
The patient’s tumor tissue was analyzed with a Tempus xT gene panel using NGS for muta-
tion testing (Beaubier et al. 2019). Longitudinal analysis of ctDNA was performed on the pa-
tient’s peripheral blood using Guardant360 CDx before starting nivolumab and olaparib and
at 2 mo (Lanman et al. 2015).
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